Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage.

Journal of biomedical science - 11 Jul 2024

Kotani Hiroshi, Oshima Hiroko, Boucher Justin C, Yamano Tomoyoshi, Sakaguchi Hiroyuki, Sato Shigeki, Fukuda Koji, Nishiyama Akihiro, Yamashita Kaname, Ohtsubo Koushiro, Takeuchi Shinji, Nishiuchi Takumi, Oshima Masanobu, Davila Marco L, Yano Seiji

Abstract excerpt

BACKGROUND: KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRASG12C inhibitors have recently been approved, effective precision therapies have not yet been established for all KRAS-mutant cancers. Many treatments for KRAS-mutant cancers, including epigenome-targeted drugs, are currently under investigation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to DNA Damage

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins c-myc

Share to Proto-Oncogene Proteins p21(ras)

Share to Sumoylation

Source

Open in PubMed Open full text

Identifiers

PMID: 38992694
DOI: 10.1186/s12929-024-01060-3
PMCID: PMC11238369

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage.PMID 38992694Read ↗

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Semantic proximity Read ↗

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphomaSemantic proximity Read ↗

MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Therapeutic Potential of Targeting the SUMO Pathway in CancerSemantic proximity Read ↗

The SUMO pathway in pancreatic cancer: insights and inhibitionSemantic proximity Read ↗

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor MicroenvironmentSemantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerSemantic proximity Read ↗

KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer.Semantic proximity Read ↗

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Semantic proximity Read ↗

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven TumorigenesisSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.